Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.

Blood
Alan CohenFernando Tricta

Abstract

The identification of a safe, orally active iron chelator is critically important for the prevention of morbidity and early death in patients receiving regular red cell transfusions. Based on our findings in a 1-year multicenter, prospective study of the safety and efficacy of deferiprone in patients with thalassemia major, we have extended the treatment period to 4 years. The mean dose of the chelator was 73 mg/kg per day during 531 patient-years. The rates of agranulocytosis (absolute neutrophil count [ANC] < 500 x 10(9)/L) and milder forms of neutropenia (ANC, 500-1500 x 10(9)/L) were 0.2 and 2.8 per 100 patient-years, respectively. Neutropenia occurred significantly more commonly in patients with intact spleens. Gastrointestinal and joint symptoms decreased significantly after the first year of therapy, and led to discontinuation of deferiprone in only one patient in years 2 to 4. The mean alanine aminotransferase (ALT) value of 71 U/L after 4 years of therapy was significantly higher than the baseline value of 61 U/L. Trend analysis showed no increase in the ALT levels or the percentage of patients with ALT levels greater than twice the upper limit of the reference range. Ferritin levels did not change significantly from t...Continue Reading

References

Nov 1, 1994·European Journal of Haematology·F N al-RefaieA V Hoffbrand
Apr 6, 1995·The New England Journal of Medicine·N F OlivieriG Koren
May 1, 1994·British Journal of Haematology·F N al-RafaieA V Hoffbrand
Sep 1, 1994·The New England Journal of Medicine·G M BrittenhamJ W Harris
Sep 1, 1994·The New England Journal of Medicine·N F OlivieriA R Cohen
Jul 21, 1998·Annals of the New York Academy of Sciences·A CohenF Tricta
Aug 13, 1998·The New England Journal of Medicine·N F OlivieriK A Fleming
Nov 25, 1998·British Journal of Haematology·B WonkeA V Hoffbrand
Feb 26, 2000·British Journal of Haematology·A R CohenF Tricta
Apr 25, 2001·European Journal of Clinical Pharmacology·R ArborettiUNKNOWN Italian Colaborative Group on Thalassarmia
Nov 13, 2001·British Journal of Haematology·J B Porter
Jun 18, 2002·Blood Cells, Molecules & Diseases·Aurelio MaggioMassimo Midiri
Jul 9, 2002·British Journal of Haematology·Adriana CeciFernando Tricta

❮ Previous
Next ❯

Citations

Apr 6, 2005·Annals of Hematology·Ersi VoskaridouDimitris Loukopoulos
Jul 19, 2005·Annals of Hematology·Massimo Franchini
Aug 6, 2009·Annals of Hematology·Inusha PanigrahiRashmi R Das
Feb 15, 2011·Annals of Hematology·Michel DelforgeChristophe Ravoet
Feb 1, 2007·Current Hematologic Malignancy Reports·Peter-D Jensen
Mar 2, 2005·Best Practice & Research. Clinical Haematology·A Victor Hoffbrand
Sep 9, 2005·The New England Journal of Medicine·Thomas P Stossel
Oct 3, 2009·Journal of Biomolecular Structure & Dynamics·A A Moosavi-MovahediA A Saboury
Feb 24, 2005·Current Opinion in Hematology·Melody J Cunningham, David G Nathan
Jan 26, 2010·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Antonio Cao, Renzo Galanello
Oct 6, 2010·Journal of Pediatric Hematology/oncology·Moshen S ElAlfyAmal El-Beshlawy
Sep 10, 2011·Journal of Paediatrics and Child Health·Saumya Shekhar JamuarIvy Swee Lian Ng
Feb 14, 2004·BMJ : British Medical Journal·Julian Savulescu
Jul 28, 2009·Annual Review of Medicine·Maria Domenica Cappellini, Paolo Pattoneri
Dec 14, 2011·Hematology·Janet L Kwiatkowski
Mar 24, 2007·Blood·Nathalie BoddaertZ Ioav Cabantchik
Aug 5, 2011·Blood·Eliezer A Rachmilewitz, Patricia J Giardina
Nov 1, 2012·Journal of Blood Medicine·Vasilios BerdoukasThomas Coates
Nov 10, 2009·Therapeutics and Clinical Risk Management·Ali Taher, Maria Domenica Cappellini
Mar 27, 2009·CNS Drugs·Amy Y TsouDavid R Lynch
Jul 21, 2011·Pediatric Reports·Antonio CaoRenzo Galanello
Jan 1, 2009·Mediterranean Journal of Hematology and Infectious Diseases·Paolo Cianciulli
Feb 11, 2014·Best Practice & Research. Clinical Haematology·David P Steensma, Norbert Gattermann
Feb 8, 2014·Cardiology in Review·Vinay GulatiWilliam H Frishman
Jan 25, 2014·Chemical Reviews·Katja Dralle Mjos, Chris Orvig
Nov 21, 2013·Antioxidants & Redox Signaling·David DevosRégis Bordet
Jul 30, 2014·Hematology/oncology Clinics of North America·Maria Marsella, Caterina Borgna-Pignatti
May 22, 2010·Advances in Hematology·Radha RaghupathyJane A Little
Sep 28, 2010·Advances in Hematology·Vinod Pullarkat
Apr 16, 2010·Canadian Journal of Physiology and Pharmacology·Or KakhlonZ Ioav Cabantchik
Nov 7, 2008·Wiener klinische Wochenschrift·Reinhard StauderPeter Valent
Mar 8, 2012·Dalton Transactions : an International Journal of Inorganic Chemistry·Yu-Lin ChenRobert C Hider
Aug 3, 2012·Dalton Transactions : an International Journal of Inorganic Chemistry·Yu-Lin ChenRobert C Hider
Oct 21, 2006·Current Opinion in Hematology·Claudia R MorrisMark C Walters
Feb 26, 2008·Leukemia & Lymphoma·Sameer MaheshAmit Verma
Nov 13, 2007·Hemoglobin·Marwan Sheikh-TahaAli Taher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.